The outlook of companies tied to Sildenafil's history presents a challenging investment picture . While the initial boom generated substantial returns , generic alternatives have significantly diminished sales . Investing in associated pharmaceutical companies now requires a discerning assessment of proprietary rights , evolving patient changes, an